REG - ValiRx PLC - Inaphaea Commercial Update

ValiRxAnnouncement

18/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250918:nRSR7851Za&default-theme=true

RNS Number : 7851Z  ValiRx PLC  18 September 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

Inaphaea Commercial Update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to provide the
following updates on its wholly owned subsidiary Inaphaea Limited
("Inaphaea").

Inaphaea is pleased to announce that, as it continues to expand its capability
partnerships, it has signed a Collaboration Agreement with Swiss techbio
company, TwinEdge Bioscience ("TwinEdge"). TwinEdge combine cutting-edge
computational biology, artificial intelligence, and personalized medicine to
transform how new cancer therapies are developed. Under the agreement,
TwinEdge will combine their proprietary methodology with drug response
datasets obtained from Inaphaea's Patient derived Cells (PDCs) to create
"patient avatars" which are digitally actionable representations of the
patients' tumours, ready for testing with new drugs in "in-avatar" trials.
This AI aided classification of responses in PDCs can be used to provide
mechanistic insight, predict response of new, or repurposed, drugs and
identify biomarkers for patient selection in-silico in what will be one of the
world's largest population of digital twins created by TwinEdge.

As part of its continued service and product development, Inaphaea has also
signed a Material Transfer Agreement with Nottingham University Hospitals NHS
Trust to obtain new PDC models, prioritising ovarian, breast, lung and
prostate cancer samples with matched blood plasma, white blood cells and
ascites/pleural fluids with full ethics and commercial use consent. These
prospectively collected samples, with associated clinical data, will be used
in advanced 3D models to understand host immune engagement, for example with
CytoLytix oncolytic peptide program, as well as external client projects.

Additionally, a series of 6 colorectal Cancer PDC models have also been
transferred to Cellomatics Ltd under the Evaluation Use Agreement, announced
on 30 April 2025, in parallel with characterisation by low pass sequencing
underway at Inaphaea.

Inaphaea is also pleased to announce that its collaborative 3K Screen program
with Dominion, announced on 12 May 2025, has identified around 250 hits from
the initial screen against 5 different models. Around 50 of these molecules,
included as controls to validate the approach, have known activity in cancer.
Inaphaea and Dominion have reviewed the initial hits and prioritised them
based on selection criteria including oral availability of the drugs, freedom
to operate regarding current patent position and likely patient positioning
for unmet clinical need. A top 10 set of molecules has been selected for
inclusion in the next phase which included testing of full dose response
curves in selected Patient Derived Models at Inaphaea and Dominion. The data
generated will be processed in TwinEdge's digital twin AI platform to support
new patent filings and initial commercial discussions with potential licensees
as well as application for non-dilutive grant funding to support further
development of these and other assets from the 3K screen. Sales and marketing
for PredictRx personalised therapy selection has also been initiated by
Dominion with initial sales anticipated in Q4.

 

Mark Eccleston, CEO of ValiRx commented "Our new partnership with TwinEdge
Bioscience is a huge step forward in both our service and in house development
capabilities at Inaphaea and for the broader ValiRx group. Digitising our 2D
and 3D PDC models further leverages the valuable RNA-seq and treatment
response data sets we have and provides another New Approach Methodology (NAM)
to accelerate our translational drug development programs. The Patient Avatar
approach enables unprecedented large-scale clinical insight at translational
and early clinical decision points allowing an in-silico screen of 10,000
digitised patents and counting. This approach will accelerate internal and
customer drug development programs and provide clinical insight at a fraction
of the cost of a real-world clinical trial. The predictive biomarker readouts
will also streamline future in-human and in-canine clinical trials by matching
the right patient with the right drug, increasing the chances of success and
maximising asset value to prospective licensees through an expedited clinical
trails pathway."

 

"We are also pleased that the additional quality control work and data
generation through low pass sequencing is being recognised with colorectal
cancer PDCs now under evaluation with Cellomatics. The new prospective sample
collection capability established with the local NHS trust will support
ongoing PDC development and supply agreements whilst also expanding our
capabilities in the immune oncology space through the ability to procure
patient blood samples matched to the PDC models. This is a major advantage for
both our internal programs such as Cytolytix, especially when combined with
advanced model platforms through our collaborations with ScreenIn3d and
VoxCell, as well as for service provision to clients. Our Internal programmes
will also provide excellent case studies to support further client project
procurement."

 

"Finally, building on our commitment to realise the potential of the assets
within Inaphaea, we are also very excited to announce the selection of the top
10 prioritised candidates from our 3k-screen collaboration with Dominion. We
will be developing a data package for these assets based on PDC profiling,
initially in Ovarian cancer, and our new in-silico clinical prediction and
precision biomarker approach for patient selection with TwinEdge providing a
virtual clinical trial data set to take forward into partnering discussions
whilst actively applying for grant funding to continue their development.
We're also working with Dominion to support outreach and promotion of the
PredictRx platform with early revenue anticipated as soon as Q4 2025."

 

Michael Prosser, CEO of TwinEdge Commented "This partnership with ValiRx and
Inaphaea marks a significant milestone, both for TwinEdge Bioscience as a
company, and for the broader deployment of New Approach Methodologies (NAMs)
in oncology drug development. Together, we are combining deep scientific
expertise with complementary innovative platforms to generate more predictive
insights, reduce reliance on animal models, and ultimately accelerate better
therapies to patients. At TwinEdge we are proud to be at the forefront of
Digital Twin technology, and by delivering population-scale insight throughout
the drug development process, we enable our clients to make better decisions
regarding which translational programmes progress to clinical trials, and how
those clinical trials are designed and run. We aim to redefine translational
models, speed decision-making, and support the development of next-generation
oncology treatments. Through partners such as ValiRx and Inaphaea, we can help
translate science into real patient outcomes."

 

Anthony Holmes, CEO of Dominion commented "We're delighted with the progress
of our collaboration with Inaphaea on the 3K Screen programme. The
identification of around 250 potential hits from this comprehensive drug
repositioning screen represents a significant milestone in our joint efforts
to unlock new cancer treatment opportunities from existing approved drugs. The
selection of our top 10 priority candidates for advanced testing demonstrates
the quality and commercial potential within this dataset. This collaboration
perfectly complements our PredictRx personalised therapy platform, which we're
excited to bring to market. By combining Inaphaea's extensive biobank with our
analytical capabilities and fresh sample collection expertise, we're creating
a powerful pipeline of both repositioned drugs and personalised treatment
solutions that could significantly benefit cancer patients while generating
value for pharmaceutical partners."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/yaG96r

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDGGDCSGBDGUR